Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Breast Neoplasm Female × Anastrozole × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 182 Neoplasm Metastasis 11 Neoplasms 10 Carcinoma, Intraductal, Noninfiltrating 8 Breast Neoplasms, Male 6 Breast Carcinoma In Situ 5 Advanced Breast Cancer 5 Triple Negative Breast Neoplasms 4 Endometrial Neoplasms 4 Breast Diseases 4 Ovarian Neoplasms 3 Breast Cancer Metastatic 3 Neoplasms by Site 2 Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor 1 Skin Diseases 1 Sexual Dysfunction, Physiological 1 Seizures 1 Sarcoma 1 Recurrence 1 Quality of Life 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Osteoporosis 1 Multiple Endocrine Neoplasia Type 1 1 Low Grade Serous Ovarian Cancer 1 Locoregional Recurrence 1 Lethal Congenital Contracture Syndrome 2 1 Joint Diseases 1

Interventions

venetoclax 1 pyrotinib 1 pertuzumab 1 palbociclib 1 dalpiciclib 1 anlotinib 1 Tretinoin 1 Trastuzumab 1 Ropivacaine 1 Radiosurgery 1 Propofol 1 Paclitaxel 1 Ondansetron 1 Morphine 1 Letrozole 1 Induction Chemotherapy 1 Fulvestrant 1 Etoricoxib 1 Docetaxel 1 Diagnostic Imaging 1 Carboplatin 1 Capecitabine 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04113863 2025-12-18

ATRA

Mario Negri Institute for Pharmacological Research

Phase 2 Terminated

Breast Neoplasm Female

Data powered by HemOnc (CC BY 4.0) Colophon ⚡